{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:39:43Z","timestamp":1761057583704,"version":"3.37.3"},"reference-count":17,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2002,9]]},"DOI":"10.1124\/dmd.30.9.1013","type":"journal-article","created":{"date-parts":[[2003,1,15]],"date-time":"2003-01-15T23:17:35Z","timestamp":1042672655000},"page":"1013-1021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Disposition of a Specific Cyclooxygenase-2 Inhibitor, Valdecoxib, in Human"],"prefix":"10.1016","volume":"30","author":[{"given":"Josh J.","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai-chang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Roy","family":"Bible","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz","family":"Karim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.A.","family":"Findlay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.30.9.1013_bib1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2165\/00003495-200059040-00017","article-title":"Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.","volume":"59","author":"Clemett","year":"2000","journal-title":"Drugs"},{"key":"10.1124\/dmd.30.9.1013_bib2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0889-857X(05)70073-9","article-title":"Selective cyclooxygenase-2 inhibitors.","volume":"25","author":"Golden","year":"1999","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1124\/dmd.30.9.1013_bib3","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0149-2918(00)80005-3","article-title":"Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.","volume":"21","author":"Goldenberg","year":"1999","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.30.9.1013_bib4","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1572-0241.2000.02194.x","article-title":"Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.","volume":"95","author":"Goldstein","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1124\/dmd.30.9.1013_bib5","unstructured":"Grzesiok A, Weber H, Pino RZ, Feelisch M (1994) Release of nitric oxide upon oxidative metabolism accounts for the vasodilator activity of Piloty's acid No. 8 - The Biology of Nitric Oxide Part 4 - Enzymology, Biochemistry and Immunology (Moncada S, Feelisch M, Busse R, Higgs EA ed) pp 238\u2013241, Portland Press Ltd., London."},{"key":"10.1124\/dmd.30.9.1013_bib6","first-page":"838","article-title":"1996 ASPET N-glucuronidation of xenobiotics symposium: species differences in N-glucuronidation.","volume":"26","author":"Lee","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.9.1013_bib7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/00912700022008766","article-title":"Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial.","volume":"40","author":"Leese","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.30.9.1013_bib8","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0022-3565(25)22544-7","article-title":"In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages.","volume":"270","author":"Masferrer","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.30.9.1013_bib9","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1172\/JCI114850","article-title":"Selective regulaton of cellular cyclooxygenase by dexamethasone and endotoxin in mice.","volume":"86","author":"Masferrer","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.30.9.1013_bib10","first-page":"108","article-title":"Celecoxib for rheumatoid arthritis.","volume":"49","author":"Megeff","year":"2000","journal-title":"J Fam Pract"},{"issue":"Suppl 49","key":"10.1124\/dmd.30.9.1013_bib11","first-page":"6","article-title":"The discovery and function of COX-2.","volume":"24","author":"Needleman","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1124\/dmd.30.9.1013_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1042\/bj3120333","article-title":"Oxidative release of nitric oxide accounts for guanylyl cyclase stimulating, vasodilator and anti-platelet activity of Piloty's acid: a comparison with Angeli's salt.","volume":"312","author":"Ruben","year":"1995","journal-title":"Biochem J"},{"key":"10.1124\/dmd.30.9.1013_bib13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/9465","article-title":"COX-2 inhibitors\u2013is there cause for concern? [news; comment].","volume":"5","author":"Seibert","year":"1999","journal-title":"Nat Med"},{"key":"10.1124\/dmd.30.9.1013_bib14","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.","volume":"342","author":"Steinbach","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.30.9.1013_bib15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1021\/jm990577v","article-title":"4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.","volume":"43","author":"Talley","year":"2000","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.30.9.1013_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1742-1241.2000.tb11832.x","article-title":"The future of NSAID therapy: selective COX-2 inhibitors [editorial].","volume":"54","author":"Vane","year":"2000","journal-title":"Int J Clin Pract"},{"key":"10.1124\/dmd.30.9.1013_bib17","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1073\/pnas.91.6.2046","article-title":"Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation.","volume":"91","author":"Vane","year":"1994","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624045033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624045033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.30.9.1013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:14:23Z","timestamp":1739902463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624045033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["S0090955624045033"],"URL":"https:\/\/doi.org\/10.1124\/dmd.30.9.1013","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2002,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disposition of a Specific Cyclooxygenase-2 Inhibitor, Valdecoxib, in Human","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.30.9.1013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2002 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}